Fuzeon Related Published Studies
Well-designed clinical trials related to Fuzeon (Enfuvirtide)
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. [2011.09]
The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy. [2011.01]
Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138). [2010.09]
Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients. [2009.07.17]
A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study. [2008.12]
Adherence to enfuvirtide and its impact on treatment efficacy. [2008.02]
A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study). [2008]
Short communication safety, tolerability and pharmacokinetics of enfuvirtide administered by a needle-free injection system compared with subcutaneous injection. [2008]
Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration. [2006.12]
Viral Decay Dynamics in HIV-Infected Patients Receiving Ritonavir-Boosted Saquinavir and Efavirenz With or Without Enfuvirtide: A Randomized, Controlled Trial (HIV-NAT 012). [2006.11.01]
HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. [2006.07.15]
Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. [2006.05]
A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide. [2006]
Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients. [2006]
Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). [2006]
A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. [2006]
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. [2005.12.01]
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. [2005.12.01]
Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen. [2004.09.01]
[Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1] [2004.09]
Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients. [2004.06]
Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. [2004.02]
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. [2003.08]
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. [2003.05.29]
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. [2003.05.29]
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. [2002.07.01]
Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition. [2002.07]
Well-designed clinical trials possibly related to Fuzeon (Enfuvirtide)
Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients. [2010.11]
Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials. [2010.11]
Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen. [2010.09.24]
Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2. [2010.07]
Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials. [2010.01]
Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience. [2010]
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. [2010]
Effects of etravirine versus placebo on health-related quality of life in
treatment-experienced HIV patients as measured by the functional assessment of
human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials. [2010]
Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. [2009.04]
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. [2008.07.24]
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. [2007.07.07]
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. [2007.07.07]
Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA. [2007.05]
Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. [2007.01.11]
Prognostic staging of extensively pretreated patients with advanced HIV-1 disease. [2005.11]
Subcutaneous injection survey: psychometric evaluation of a treatment satisfaction instrument associated with a novel HIV medication. [2002.09]
Other research related to Fuzeon (Enfuvirtide)
Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study. [2011.12.02]
Genotypic analysis of the gp41 HR1 region from HIV-1 isolates from enfuvirtide-treated and untreated patients. [2011.08]
Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial. [2011.07]
Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide. [2011.05]
Enfuvirtide injection site reactions: a clinical and histopathological appraisal. [2011.02]
The suppression of immune activation during enfuvirtide-based salvage therapy is associated with reduced CCR5 expression and decreased concentrations of circulating interleukin-12 and IP-10 during 48 weeks of longitudinal follow-up. [2011.02]
Modelling the effects of adherence to the HIV fusion inhibitor enfuvirtide. [2011.01.07]
Enfuvirtide injection site reactions: a clinical and histopathological appraisal. [2011]
Interaction between enfuvirtide, an injectable fusion inhibitor, and niacin in an HIV-infected patient. [2010.12]
A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s). [2010.11]
Enfuvirtide: from basic investigations to current clinical use. [2010.11]
Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide. [2010.09]
Enfuvirtide administration in HIV-positive transgender patient with soft tissue augmentation: US evaluation. [2010.07]
[Enfuvirtide in the treatment of AIDS patient: the turning point]. [2010.06]
Short communication: high polymorphism rates in the HR1 and HR2 gp41 and presence of primary resistance-related mutations in HIV type 1 circulating in Brazil: possible impact on enfuvirtide efficacy. [2010.03]
Short communication: evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials. [2010.03]
Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid. [2010.02.01]
No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. [2010.01.15]
Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy? [2010.01]
Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity. [2010.01]
Impact on health-related quality of life of a switch from enfuvirtide to
raltegravir among multidrug-resistant HIV-1-infected patients: a randomized
open-label trial (EASIER-ANRS 138). [2010]
Efficacy and safety of a salvage regimen based on tipranavir, enfuvirtide and three nucleoside analogues in HIV1 infected patients with clinical progression: 96-week evaluation. [2009.12]
Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life. [2009.12]
Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression. [2009.11]
Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists]. [2009.11]
Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. [2009.10.15]
Enfuvirtide: a safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantation. [2009.10]
Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. [2009.08.01]
Altered bystander apoptosis induction and pathogenesis of enfuvirtide-resistant HIV type 1 Env mutants. [2009.08]
Analysis of HIV type 1 gp41 and enfuvirtide susceptibility among men in the United States who were HIV infected prior to availability of HIV entry inhibitors. [2009.07]
Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals. [2009.07]
Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure. [2009.06.01]
A delayed hypersensitivity reaction to enfuvirtide after rechallenge. [2009.04]
The fusion inhibitor enfuvirtide in recent antiretroviral strategies. [2009.03]
[Enfuvirtide in HIV patients: a nursing guideline for medication management] [2009.02]
A 12-year-old boy with multidrug-resistant human immunodeficiency virus type 1 successfully treated with HAART including ritonavir-boosted tipranavir oral solution and enfuvirtide. [2009.01.28]
Use of darunavir and enfuvirtide in a pregnant woman. [2008.12]
Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study. [2008.12]
Postmarketing use of enfuvirtide in veterans: provider compliance with criteria for use, overall efficacy, and tolerability. [2008.11]
Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study. [2008.11]
A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study. [2008.09.08]
Reassessment of enfuvirtide's role in the management of HIV-1 infection. [2008.09]
HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide. [2008.09]
Successful prevention of multidrug resistant HIV mother-to-child transmission with enfuvirtide use in late pregnancy. [2008.09]
Staphylococcus aureus brain abscess in an HIV-infected patient exposed to enfuvirtide. [2008.09]
Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide. [2008.08.15]
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. [2008.08]
A report on the effect of commencing enfuvirtide on peripheral neuropathy. [2008.08]
Impact of education and support on the tolerability and quality of life in a cohort of HIV-1 infected patients treated with enfuvirtide (SURCOUF Study). [2008.07]
Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. [2008.06.19]
An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS). [2008.06]
Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations. [2008.06]
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. [2008.05.16]
Immunologic benefits of enfuvirtide in patients enrolled in a drug assistance program. [2008.05]
Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function. [2008.03.01]
Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients. [2008.03]
Patients' perception and effectiveness of a treatment containing enfuvirtide when used in HIV-infected patients without very advanced disease. [2008.03]
Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. [2008]
|
